Celgene Corp

CELG-Q

NASDAQ:CELG

108.24
0.00 (0.00%)
Celgene Corporation is an American biotechnology company that discovers, develops and commercializes medicines for cancer and inflammatory disorders. It is incorporated in Delaware and headquartered in Summit, New Jersey.
More at Wikipedia

Analysis and Opinions about CELG-Q

Signal
Opinion
Expert
SELL
SELL
November 27, 2019
He sold out because it's going to be merged with Bristol Myers, they received full value, and there's always deal risk. Celgene owners may get a premium if 3 drugs come to market and exceeded certain thresholds. This is a side bet, and not the way he likes to invest.
Celgene Corp (CELG-Q)
November 27, 2019
He sold out because it's going to be merged with Bristol Myers, they received full value, and there's always deal risk. Celgene owners may get a premium if 3 drugs come to market and exceeded certain thresholds. This is a side bet, and not the way he likes to invest.
Gordon Reid
President, GoodReid Investment Counsel
Price
$108.240
Owned
No
PAST TOP PICK
PAST TOP PICK
October 16, 2019

(A Top Pick Oct 22/18, Up 25%) The Bristol acquisition was perfect. CELG boasts strong competitive barriers to their products and their product pipeline will pleasantly surprise the market. He's not worried about the US election and the negative effect on US healthcare; in fact, he loves buying stocks when others fear or hate them.

Celgene Corp (CELG-Q)
October 16, 2019

(A Top Pick Oct 22/18, Up 25%) The Bristol acquisition was perfect. CELG boasts strong competitive barriers to their products and their product pipeline will pleasantly surprise the market. He's not worried about the US election and the negative effect on US healthcare; in fact, he loves buying stocks when others fear or hate them.

Ashley Misquitta, CFA
Senior Portfolio Manager, Empire Life
Price
$100.970
Owned
Yes
COMMENT
COMMENT
September 25, 2019

He started buying BMY-N ahead of the merger discussions with CELG-Q. If the merger fails, holding the buyer is safer as arbitragers unwind hedges. The combined company would be a good cash flow generator, which would help internal growth and debt pay down.

Celgene Corp (CELG-Q)
September 25, 2019

He started buying BMY-N ahead of the merger discussions with CELG-Q. If the merger fails, holding the buyer is safer as arbitragers unwind hedges. The combined company would be a good cash flow generator, which would help internal growth and debt pay down.

John Kim
Portfolio Manager, Aston Hill Financial
Price
$98.560
Owned
Unknown
DON'T BUY
DON'T BUY
August 6, 2019

Heading into the election cycle, pharma will be under pressure. He prefers being into medical devices. He has a hard time being excited about either CELG or BMY, especially if the market is currently jittery. (Analysts’ price target is $100.33)

Celgene Corp (CELG-Q)
August 6, 2019

Heading into the election cycle, pharma will be under pressure. He prefers being into medical devices. He has a hard time being excited about either CELG or BMY, especially if the market is currently jittery. (Analysts’ price target is $100.33)

David Burrows
President & Chief Investment Strategist, Barometer Capital Management
Price
$93.570
Owned
Unknown
PAST TOP PICK
PAST TOP PICK
May 3, 2019
(A Top Pick Mar 21/18, Up 10%) Sold it because it's getting taken out by Bristol Myers.
(A Top Pick Mar 21/18, Up 10%) Sold it because it's getting taken out by Bristol Myers.
Paul MacDonald
Chief Investment Officer & Portfolio Manager, Harvest Portfolios Group
Price
$96.780
Owned
No
BUY
BUY
April 22, 2019
Bistol-Myers bought it which is good news for Celgene holders.
Celgene Corp (CELG-Q)
April 22, 2019
Bistol-Myers bought it which is good news for Celgene holders.
Gordon Reid
President, GoodReid Investment Counsel
Price
$93.420
Owned
Yes
PAST TOP PICK
PAST TOP PICK
April 8, 2019
(A Top Pick May 30/18, Up 22%) They have a lot of new products in their patent portfolio. They are being acquired. It would be a nice speculative holding in the marketplace when it closes.
Celgene Corp (CELG-Q)
April 8, 2019
(A Top Pick May 30/18, Up 22%) They have a lot of new products in their patent portfolio. They are being acquired. It would be a nice speculative holding in the marketplace when it closes.
Bruce Murray
CEO & Chief Investment Officer, The Murray Wealth Group
Price
$95.050
Owned
Yes
PAST TOP PICK
PAST TOP PICK
February 11, 2019
(A Top Pick Mar 20/18, Down 0.2%) It was one of his hopes in the medical area for great growth. They are being acquired. He is going to keep holding it.
Celgene Corp (CELG-Q)
February 11, 2019
(A Top Pick Mar 20/18, Down 0.2%) It was one of his hopes in the medical area for great growth. They are being acquired. He is going to keep holding it.
Bruce Murray
CEO & Chief Investment Officer, The Murray Wealth Group
Price
$89.870
Owned
Yes
SELL
SELL
January 10, 2019
Having issues in terms of competition. They wanted to merge with Bristol. She doesn't think the combination makes it a better company. She would sell on the announcement (as the stock lifted).
Celgene Corp (CELG-Q)
January 10, 2019
Having issues in terms of competition. They wanted to merge with Bristol. She doesn't think the combination makes it a better company. She would sell on the announcement (as the stock lifted).
Christine Poole
CEO & Managing Director, GlobeInvest Capital Management
Price
$86.950
Owned
No
BUY
BUY
December 31, 2018
It has a better growth pipeline. Biotech in the US is probably one of the better areas of growth. He prefers the IBB-Q ETF. He likes the sector. There is good growth potential.
Celgene Corp (CELG-Q)
December 31, 2018
It has a better growth pipeline. Biotech in the US is probably one of the better areas of growth. He prefers the IBB-Q ETF. He likes the sector. There is good growth potential.
John Zechner
Chairman, J. Zechner & Assoc
Price
$64.090
Owned
Unknown
TOP PICK
TOP PICK
December 3, 2018
They're in oncology, particularly blood cancer. They've had some headwinds in some FDA submissions due to mistakes by management. So, the stock got punished. It's trading at 6.5x and generating a ton of cash flow as good test results come in. They are diversifying as they acquire. Hoeps investor sentiment improves. (Analysts’ price target is $108.61)
Celgene Corp (CELG-Q)
December 3, 2018
They're in oncology, particularly blood cancer. They've had some headwinds in some FDA submissions due to mistakes by management. So, the stock got punished. It's trading at 6.5x and generating a ton of cash flow as good test results come in. They are diversifying as they acquire. Hoeps investor sentiment improves. (Analysts’ price target is $108.61)
Paul MacDonald
Chief Investment Officer & Portfolio Manager, Harvest Portfolios Group
Price
$73.420
Owned
Yes
DON'T BUY
DON'T BUY
November 12, 2018
They have drugs going off patent in 2020. They have 5 big names coming into trials at the same time. He is not clear on what will cause it to bounce. Don't buy lows. The price is confirmed by relative strength.
Celgene Corp (CELG-Q)
November 12, 2018
They have drugs going off patent in 2020. They have 5 big names coming into trials at the same time. He is not clear on what will cause it to bounce. Don't buy lows. The price is confirmed by relative strength.
Cameron Hurst
Chief Investment Officer, Equium Capital Management
Price
$71.020
Owned
Unknown
TOP PICK
TOP PICK
October 22, 2018

(no dividend yield, Analysts' price target: not given) A global biotech focussed on cancer. They've stumbled recently, but phase 3 trials have been positive. Their drugs have a diminished chance of going generic, according to data. Attractive value. smart managers and a rich pipeline of drugs coming.

Celgene Corp (CELG-Q)
October 22, 2018

(no dividend yield, Analysts' price target: not given) A global biotech focussed on cancer. They've stumbled recently, but phase 3 trials have been positive. Their drugs have a diminished chance of going generic, according to data. Attractive value. smart managers and a rich pipeline of drugs coming.

Ashley Misquitta, CFA
Senior Portfolio Manager, Empire Life
Price
$80.610
Owned
Yes
DON'T BUY
DON'T BUY
October 10, 2018

They have a good cash float, which will lead to a share buyback, he feels. He sees resistance at $90-$100, which will be tough to battle through. He would suggest taking a loss if you hold this one, because the future capex requirements will be more expensive as interest rates rise. He would prefer IHI-N if you like the healthcare space as he does.

Celgene Corp (CELG-Q)
October 10, 2018

They have a good cash float, which will lead to a share buyback, he feels. He sees resistance at $90-$100, which will be tough to battle through. He would suggest taking a loss if you hold this one, because the future capex requirements will be more expensive as interest rates rise. He would prefer IHI-N if you like the healthcare space as he does.

Cameron Hurst
Chief Investment Officer, Equium Capital Management
Price
$84.230
Owned
No
DON'T BUY
DON'T BUY
September 18, 2018

They were working on some drug trials which didn't work as expected. Acqusitions didnt work out either The balance sheet is weaker than before. Some of their drugs will soon lose their patent.

Celgene Corp (CELG-Q)
September 18, 2018

They were working on some drug trials which didn't work as expected. Acqusitions didnt work out either The balance sheet is weaker than before. Some of their drugs will soon lose their patent.

John O'Connell, CFA
Chairman and CEO, Davis Rea
Price
$87.610
Owned
No
HOLD
HOLD
September 12, 2018

Stock price has pushed up above the 200-day moving average. Longer term, this is an important space to be in. Good pipeline. Hold onto it at this point. Valuation is cheap. Trading at 9x earnings, expected 20% growth rate.

Celgene Corp (CELG-Q)
September 12, 2018

Stock price has pushed up above the 200-day moving average. Longer term, this is an important space to be in. Good pipeline. Hold onto it at this point. Valuation is cheap. Trading at 9x earnings, expected 20% growth rate.

Stan Wong
Director & Portfolio Manager, Private Wealth Management, ScotiaMcleod
Price
$86.800
Owned
No
PAST TOP PICK
PAST TOP PICK
August 21, 2018

(A Top Pick September 19, 2017. Down 37%). About 70% of the stocks he buys turn into gains. Celgene was one of the losses. Generally, the goal is to cut losses quickly. However, Celgene’s earnings have been rising, not falling. The difference is that the market has lost confidence in the company and dropped the valuation from a premium level to an extreme discount. The company has had some missteps, failed drug trials, that pare down its long term growth. Looking at Celgene at today’s price, he is keeping it because it offers good value at this price.

Celgene Corp (CELG-Q)
August 21, 2018

(A Top Pick September 19, 2017. Down 37%). About 70% of the stocks he buys turn into gains. Celgene was one of the losses. Generally, the goal is to cut losses quickly. However, Celgene’s earnings have been rising, not falling. The difference is that the market has lost confidence in the company and dropped the valuation from a premium level to an extreme discount. The company has had some missteps, failed drug trials, that pare down its long term growth. Looking at Celgene at today’s price, he is keeping it because it offers good value at this price.

Gordon Reid
President, GoodReid Investment Counsel
Price
$91.200
Owned
Yes
PARTIAL BUY
PARTIAL BUY
July 27, 2018

Nice chart. Really nice base in May/June around $79. If it can stay above $83, it’s looking pretty good. Potential to consolidate around $100, as an end of year target. If it drops another $8, start reducing. Take a small position only.

Celgene Corp (CELG-Q)
July 27, 2018

Nice chart. Really nice base in May/June around $79. If it can stay above $83, it’s looking pretty good. Potential to consolidate around $100, as an end of year target. If it drops another $8, start reducing. Take a small position only.

Jeff Parent B. Eng. FCSI CIM
VP & Portfolio Manager, Chief Investment Officer, Castlemoore Inc.
Price
$86.430
Owned
Unknown
DON'T BUY
DON'T BUY
July 18, 2018

The biotech sector is performing well. He would prefer to own the XBI-N ETF to get a basket and diversify risk.

Celgene Corp (CELG-Q)
July 18, 2018

The biotech sector is performing well. He would prefer to own the XBI-N ETF to get a basket and diversify risk.

David Burrows
President & Chief Investment Strategist, Barometer Capital Management
Price
$85.780
Owned
No
PARTIAL BUY
PARTIAL BUY
July 9, 2018

It is turning around. It got hammered and is showing some potential. It looks like it is breaking the downtrend. He is keeping a sharp eye on it. He is optimistic.

It is turning around. It got hammered and is showing some potential. It looks like it is breaking the downtrend. He is keeping a sharp eye on it. He is optimistic.

Keith Richards
Portfolio Manager, ValueTrend Wealth Management
Price
$83.850
Owned
Yes
HOLD
HOLD
July 5, 2018

Own widely. They had a number of missteps. They reduced their guidance. Great valuation. Some competitive threads coming in 2021-22. He would be cautious. (Analysts’ price target is $113.68)

Own widely. They had a number of missteps. They reduced their guidance. Great valuation. Some competitive threads coming in 2021-22. He would be cautious. (Analysts’ price target is $113.68)

Paul MacDonald
Chief Investment Officer & Portfolio Manager, Harvest Portfolios Group
Price
$80.390
Owned
No
WATCH
WATCH
June 20, 2018

He has started watching this bio-tech company as their earnings have been improving. The technical chart looks bearish to him now. He will watch them. (Analysts’ price target is $114)

Celgene Corp (CELG-Q)
June 20, 2018

He has started watching this bio-tech company as their earnings have been improving. The technical chart looks bearish to him now. He will watch them. (Analysts’ price target is $114)

Jason Del Vicario
Portfolio Manager, HollisWealth
Price
$79.770
Owned
No
BUY
BUY
June 14, 2018

This sector is fragmented and under valued. He likes it but has some short term issues that have hurt the stock. This is a negative momentum stock. Expects this to be higher in a year or 2. His favourite is Gilead in the sector.

Celgene Corp (CELG-Q)
June 14, 2018

This sector is fragmented and under valued. He likes it but has some short term issues that have hurt the stock. This is a negative momentum stock. Expects this to be higher in a year or 2. His favourite is Gilead in the sector.

Alex Ruus
Portfolio Manager, Arrow Capital Management
Price
$78.390
Owned
Unknown
TOP PICK
TOP PICK
May 30, 2018

He's long owned this. They has a nasty surprise in 2017 when a drug failed to get approval, plus other issues. Currently it's selling at 9x earnings. Firmly believe their new products--with big upside--will carry this company higher. (Analysts' price target: $111.83)

He's long owned this. They has a nasty surprise in 2017 when a drug failed to get approval, plus other issues. Currently it's selling at 9x earnings. Firmly believe their new products--with big upside--will carry this company higher. (Analysts' price target: $111.83)

Bruce Murray
CEO & Chief Investment Officer, The Murray Wealth Group
Price
$77.970
Owned
Yes
PAST TOP PICK
PAST TOP PICK
May 28, 2018

(A Top Pick May 28/17, Down 32%) It is considered best of class but stumbled and there is a negative sentiment to health care stocks. It is growing double digits but trading at a single digit multiple so he is just holding it for now.

(A Top Pick May 28/17, Down 32%) It is considered best of class but stumbled and there is a negative sentiment to health care stocks. It is growing double digits but trading at a single digit multiple so he is just holding it for now.

Teal Linde
Portfolio Manager & Publisher, Linde Equity Report, Linde Equity Report
Price
$78.630
Owned
Yes
DON'T BUY
DON'T BUY
May 28, 2018

Not cheap, based on its historic valuation. Fundamentally, it's a good business, but its chart is unhealthy. Healthcare should be in any portfolio and this is a quality company. But Celgene ranks near the bottom of his medical/health stocks, 45 out of 49.

Not cheap, based on its historic valuation. Fundamentally, it's a good business, but its chart is unhealthy. Healthcare should be in any portfolio and this is a quality company. But Celgene ranks near the bottom of his medical/health stocks, 45 out of 49.

Wolfgang Klein
Senior investment advisor, Canaccord Genuity Wealth Management
Price
$78.630
Owned
No
DON'T BUY
DON'T BUY
May 24, 2018

Sold it a while ago. Looks cheap from a valuation standpoint trading at 9 times forward earning with a 19% growth rate. Investors are concerned about their cancer drugs patents expiring in a couple of years. Dark cloud surrounding the company.

Sold it a while ago. Looks cheap from a valuation standpoint trading at 9 times forward earning with a 19% growth rate. Investors are concerned about their cancer drugs patents expiring in a couple of years. Dark cloud surrounding the company.

Stan Wong
Director & Portfolio Manager, Private Wealth Management, ScotiaMcleod
Price
$78.630
Owned
No
DON'T BUY
DON'T BUY
May 9, 2018

They completed a $5 billion buyback recently. They put up a beat on recent earnings, but there were concerns about future earnings. He does not like the space as there is a wall of sellers to overcome and bio-tech is running out of technical momentum. They have great forecasted cash flow, but watch out if they miss their guidance.

They completed a $5 billion buyback recently. They put up a beat on recent earnings, but there were concerns about future earnings. He does not like the space as there is a wall of sellers to overcome and bio-tech is running out of technical momentum. They have great forecasted cash flow, but watch out if they miss their guidance.

Cameron Hurst
Chief Investment Officer, Equium Capital Management
Price
$82.800
Owned
No
BUY
BUY
April 30, 2018

We have some erosion here. You have to live with the overreaction. Around the $75 - $85 range there is probably a really good opportunity.

Celgene Corp (CELG-Q)
April 30, 2018

We have some erosion here. You have to live with the overreaction. Around the $75 - $85 range there is probably a really good opportunity.

Hap (Robert) Sneddon FCSI
Chief Portfolio Manager & Founder, Castlemoore Inc.
Price
$87.100
Owned
Unknown
HOLD
HOLD
April 25, 2018

A disappointment, having fallen on a number of missteps including negative trial results and management issues. With biotechs, the odds of getting a drug out of trials into production is small. So, it's best to have a stable of drugs and some of them will go through. Doesn't know if this is at a bottom here, but it should do well long-term. Carries an attractive below-10x earnings multiple.

Celgene Corp (CELG-Q)
April 25, 2018

A disappointment, having fallen on a number of missteps including negative trial results and management issues. With biotechs, the odds of getting a drug out of trials into production is small. So, it's best to have a stable of drugs and some of them will go through. Doesn't know if this is at a bottom here, but it should do well long-term. Carries an attractive below-10x earnings multiple.

Gordon Reid
President, GoodReid Investment Counsel
Price
$89.200
Owned
Yes
SELL STRENGTH
SELL STRENGTH
April 2, 2018

It broke down in a lousy earnings report late last year. It broke its trend line, and more importantly the level of support at $97 has been broken. There is a lot of air or space now below this price. He is concerned about the look of it from a technical perspective. It might pop back up to its previous support level.

Celgene Corp (CELG-Q)
April 2, 2018

It broke down in a lousy earnings report late last year. It broke its trend line, and more importantly the level of support at $97 has been broken. There is a lot of air or space now below this price. He is concerned about the look of it from a technical perspective. It might pop back up to its previous support level.

Keith Richards
Portfolio Manager, ValueTrend Wealth Management
Price
$87.070
Owned
Unknown
TOP PICK
TOP PICK
March 21, 2018

Sticking with it. Valuations are too attractive to ignore. All they need are a few winning drugs and to offer proper guidance. Let's see some of their trials succeed--even good results will do. Their pipeline is too robust to stay at 8.5x forwarded earning. But management needs to regain credibility. (Analysts' target of $116.08)

Celgene Corp (CELG-Q)
March 21, 2018

Sticking with it. Valuations are too attractive to ignore. All they need are a few winning drugs and to offer proper guidance. Let's see some of their trials succeed--even good results will do. Their pipeline is too robust to stay at 8.5x forwarded earning. But management needs to regain credibility. (Analysts' target of $116.08)

Paul MacDonald
Chief Investment Officer & Portfolio Manager, Harvest Portfolios Group
Price
$88.310
Owned
Yes
PAST TOP PICK
PAST TOP PICK
March 21, 2018

(A Top Pick May 10/17, Down 26%) Was once a widely-owned, then despised, stock. New management came in, then there was a downrgade, then their Crohn's disease drug missed, then received an FDA letter for a mass drug is incomplete, which almost never happens. They've made a lot of mistakes in a short time. It still enjoys near-20% EPS growth. They have a dozen phase-two drugs in progress--a deep pipeline--but management has disappointed. That said, he continues to have faith in CELG.

Celgene Corp (CELG-Q)
March 21, 2018

(A Top Pick May 10/17, Down 26%) Was once a widely-owned, then despised, stock. New management came in, then there was a downrgade, then their Crohn's disease drug missed, then received an FDA letter for a mass drug is incomplete, which almost never happens. They've made a lot of mistakes in a short time. It still enjoys near-20% EPS growth. They have a dozen phase-two drugs in progress--a deep pipeline--but management has disappointed. That said, he continues to have faith in CELG.

Paul MacDonald
Chief Investment Officer & Portfolio Manager, Harvest Portfolios Group
Price
$88.310
Owned
Yes
TOP PICK
TOP PICK
March 20, 2018

Many growth opportunities but took some hits, falling from $150. Great opportunity now. FDA approval is coming up, so there's potential. 10.5x earnings. Could grow 15-20%. (Analysts' target of $116.32)

Celgene Corp (CELG-Q)
March 20, 2018

Many growth opportunities but took some hits, falling from $150. Great opportunity now. FDA approval is coming up, so there's potential. 10.5x earnings. Could grow 15-20%. (Analysts' target of $116.32)

Bruce Murray
CEO & Chief Investment Officer, The Murray Wealth Group
Price
$88.270
Owned
Yes
BUY
BUY
March 13, 2018

Boasts 10-11x forward earnings with a 15% growth rate. FDA trial approvals would increase investor confidence further, but they have a good pipeline of products. Likes it longer term.

Celgene Corp (CELG-Q)
March 13, 2018

Boasts 10-11x forward earnings with a 15% growth rate. FDA trial approvals would increase investor confidence further, but they have a good pipeline of products. Likes it longer term.

Stan Wong
Director & Portfolio Manager, Private Wealth Management, ScotiaMcleod
Price
$91.560
Owned
Yes
PAST TOP PICK
PAST TOP PICK
January 15, 2018

(A Top Pick April 19/17. Down 14%.) This shot up to about $140, but a key new drug application was denied. That was followed by them announcing that their 3rd quarter was a little more difficult. They still have a plethora of new drug applications, and is still one of the hottest stocks in the sector. A very solid company.

Celgene Corp (CELG-Q)
January 15, 2018

(A Top Pick April 19/17. Down 14%.) This shot up to about $140, but a key new drug application was denied. That was followed by them announcing that their 3rd quarter was a little more difficult. They still have a plethora of new drug applications, and is still one of the hottest stocks in the sector. A very solid company.

Bruce Murray
CEO & Chief Investment Officer, The Murray Wealth Group
Price
$106.000
Owned
Yes
PAST TOP PICK
PAST TOP PICK
December 7, 2017

(A Top Pick Nov 18/16. Down 16%.) Recently collapsed a bit, but still likes the name. Trading at 12X Forward Earnings with a 19% growth rate. That’s a .63 PEG ratio. They toned down guidance for 2020, and the concern is that they are going to be relying on their top cancer drug. Has been buying shares slowly. A cheap biotech name.

Celgene Corp (CELG-Q)
December 7, 2017

(A Top Pick Nov 18/16. Down 16%.) Recently collapsed a bit, but still likes the name. Trading at 12X Forward Earnings with a 19% growth rate. That’s a .63 PEG ratio. They toned down guidance for 2020, and the concern is that they are going to be relying on their top cancer drug. Has been buying shares slowly. A cheap biotech name.

Stan Wong
Director & Portfolio Manager, Private Wealth Management, ScotiaMcleod
Price
$102.730
Owned
Yes
WAIT
WAIT
November 16, 2017

One of the larger biotech companies. The big drop last month was due to a halt in one of their trials where they were developing what looked like a pretty good drug which would have been a big market. He would stay away for another month or so, but longer-term, it is a pretty good company with a portfolio of good drugs in development and good drugs in the market.

Celgene Corp (CELG-Q)
November 16, 2017

One of the larger biotech companies. The big drop last month was due to a halt in one of their trials where they were developing what looked like a pretty good drug which would have been a big market. He would stay away for another month or so, but longer-term, it is a pretty good company with a portfolio of good drugs in development and good drugs in the market.

Alex Ruus
Portfolio Manager, Arrow Capital Management
Price
$103.350
Owned
Unknown
PAST TOP PICK
PAST TOP PICK
November 13, 2017

(A Top Pick April 19/17. Down 18%.) Was one of the hottest stocks in the medical space. They have a plethora of new products in front of the FDA. It caught a cliff when 3 events happened. It was getting close to his target price of $150. One of the major analysts cut their price target which knocked it into the $130 range. FDA didn’t approve one of the new drugs knocking the price down into the $120 range. Missed a little on the 3rd quarter, so it dropped into the $100 range. He still likes it and is still buying.

Celgene Corp (CELG-Q)
November 13, 2017

(A Top Pick April 19/17. Down 18%.) Was one of the hottest stocks in the medical space. They have a plethora of new products in front of the FDA. It caught a cliff when 3 events happened. It was getting close to his target price of $150. One of the major analysts cut their price target which knocked it into the $130 range. FDA didn’t approve one of the new drugs knocking the price down into the $120 range. Missed a little on the 3rd quarter, so it dropped into the $100 range. He still likes it and is still buying.

Bruce Murray
CEO & Chief Investment Officer, The Murray Wealth Group
Price
$101.160
Owned
Yes
PAST TOP PICK
PAST TOP PICK
November 10, 2017

(A Top Pick Nov 30/16. Down 14%.) Reported earlier this month. Just prior to reporting, took a phase 3 drug out of the pipeline, that had a lot of promise. It was a drug that treated Crohn’s disease. It will build back some of the confidence, but it will take time. The return opportunities are good enough to continue holding the position.

Celgene Corp (CELG-Q)
November 10, 2017

(A Top Pick Nov 30/16. Down 14%.) Reported earlier this month. Just prior to reporting, took a phase 3 drug out of the pipeline, that had a lot of promise. It was a drug that treated Crohn’s disease. It will build back some of the confidence, but it will take time. The return opportunities are good enough to continue holding the position.

Gordon Reid
President, GoodReid Investment Counsel
Price
$102.340
Owned
Yes
BUY
BUY
October 20, 2017

This is revisiting old highs, which is a very bullish sign. In this case, it actually broke above its old highs. The current correction seems very healthy as long as it continues making higher lows. Add to your position, but keep a Stop at around $110.

Celgene Corp (CELG-Q)
October 20, 2017

This is revisiting old highs, which is a very bullish sign. In this case, it actually broke above its old highs. The current correction seems very healthy as long as it continues making higher lows. Add to your position, but keep a Stop at around $110.

William Chin
Portfolio manager, Caldwell Investment Management
Price
$121.330
Owned
Unknown
PAST TOP PICK
PAST TOP PICK
September 20, 2017

(A Top Pick Oct 4/16. Up 38%.) One of the outstanding growth stocks in the US medical field. They have a plethora of new drugs coming out. Sales are growing at about 25% per annum. With the current earnings, the target price could move into the $165-$170 due to the growth rate. The company is more likely to surprise on the upside and another $1 of earnings could give you a $20-$25 a share. This could be a $200 stock. Still a Buy.

Celgene Corp (CELG-Q)
September 20, 2017

(A Top Pick Oct 4/16. Up 38%.) One of the outstanding growth stocks in the US medical field. They have a plethora of new drugs coming out. Sales are growing at about 25% per annum. With the current earnings, the target price could move into the $165-$170 due to the growth rate. The company is more likely to surprise on the upside and another $1 of earnings could give you a $20-$25 a share. This could be a $200 stock. Still a Buy.

Bruce Murray
CEO & Chief Investment Officer, The Murray Wealth Group
Price
$144.240
Owned
Yes
TOP PICK
TOP PICK
September 19, 2017

This has done extremely well. It is growing quickly. Has a good pipeline with 4 drugs that he believes could be $1 billion or more in revenue. The biggest property they own is Revlimid. They concentrate on cancer treating drugs. Not inexpensive, but is reasonably priced. Thinks that next year they will do $8 a share in earnings, less than 20X, and growing at a rapid rate. (Analysts’ price target is $156.)

Celgene Corp (CELG-Q)
September 19, 2017

This has done extremely well. It is growing quickly. Has a good pipeline with 4 drugs that he believes could be $1 billion or more in revenue. The biggest property they own is Revlimid. They concentrate on cancer treating drugs. Not inexpensive, but is reasonably priced. Thinks that next year they will do $8 a share in earnings, less than 20X, and growing at a rapid rate. (Analysts’ price target is $156.)

Gordon Reid
President, GoodReid Investment Counsel
Price
$143.470
Owned
Yes
PAST TOP PICK
PAST TOP PICK
September 14, 2017

(Top Pick Feb 22/17, Up 19%). They have a blood cancer drug. They are testing it on all kinds of other indications. They have the ability to double the revenues based on their existing products. It is the more growthy component of his portfolio.

Celgene Corp (CELG-Q)
September 14, 2017

(Top Pick Feb 22/17, Up 19%). They have a blood cancer drug. They are testing it on all kinds of other indications. They have the ability to double the revenues based on their existing products. It is the more growthy component of his portfolio.

Paul MacDonald
Chief Investment Officer & Portfolio Manager, Harvest Portfolios Group
Price
$140.610
Owned
Yes
COMMENT
COMMENT
August 9, 2017

This is big and is more diversified than others, so you are not buying a binary outcome stock. He likes biotech, but would approach it from the equal weight standpoint by going through the SPDR S&P Biotech ETF (XBI-N). Celgene is a good name.

Celgene Corp (CELG-Q)
August 9, 2017

This is big and is more diversified than others, so you are not buying a binary outcome stock. He likes biotech, but would approach it from the equal weight standpoint by going through the SPDR S&P Biotech ETF (XBI-N). Celgene is a good name.

Cameron Hurst
Chief Investment Officer, Equium Capital Management
Price
$135.570
Owned
Unknown
PAST TOP PICK
PAST TOP PICK
August 1, 2017

(A Top Pick Oct 4/16. Up 28.79%.) Still loves this and has a target price of about $160 2-3 years out. It has some great products and has a whole plethora of new products before the FDA.

Celgene Corp (CELG-Q)
August 1, 2017

(A Top Pick Oct 4/16. Up 28.79%.) Still loves this and has a target price of about $160 2-3 years out. It has some great products and has a whole plethora of new products before the FDA.

Bruce Murray
CEO & Chief Investment Officer, The Murray Wealth Group
Price
$135.180
Owned
Yes
COMMENT